John R. Fischer | July 18, 2018
With FDA clearance now in the bag, IsoRay Inc. is prepping for the inclusion of its cesium-131 seed-based brachytherapy option in the launch of GT Medical Technologies Inc.’s GammaTile solution for the treatment of recurrent brain tumors.
Incorporating proprietary cesium-131 seeds within customizable collagen-based carriers, GammaTile Therapy delivers a highly targeted dose of intense radiation to eliminate residual cancer while limiting exposure to surrounding, healthy tissue, with the procedure taking place during the initial operation to remove the tumor.
“The option they’ve had in the past is whole brain irradiation which damages tissues and the brain structure as it goes through it,” Lori Woods, interim CEO of IsoRay, told HCB News. “Having an opportunity to put the operation in place while the surgery is being done so you don’t have to go back and open them up again, that’s effective for the OR time, it’s effective for the doctor, and it’s effective for patient follow-up.”